Nasdaq:US$16.85 (+1.02) | HKEX:HK$25.50 (-0.25) | AIM:£2.68 (+0.01)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 22 Aug 2014

Discovery of [savolitinib] as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer (Journal of Medicinal Chemistry 2014)

For detailed information, please visit:

http://pubs.acs.org/doi/abs/10.1021/jm500510f